LEIDEN, The Netherlands, Jan. 12, 2004 (PRIMEZONE) --
Monday, January 26, 2004 at 15.00 Central European Time 14.00 London Time 9.00 New York Time Please call: +31 20 531 5871 15 minutes prior to commencement and state that you are calling for Crucell's annual results.
Presentation slides will be available on the investor relations section of Crucell's website at: www.crucell.com
The conference call also will be recorded and replay is available until Monday, February 2, 2004 Dial-in number: +31 70 315 4300 Replay code: 13 88 53
About Crucell N.V.
Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria and West Nile virus. The company's development activities include collaborations with the U.S. National Institutes of Health, the U.S. Army, GlaxoSmithKline (GSK), Harvard Medical School and New York University. Crucell's products are based on its innovative PER.C6(TM) technology, which offers a safer, more efficient way to produce biologicals. The company licenses its PER.C6(TM) technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and CMO partners include Aventis, DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and currently employs 180 people. Crucell is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit www.crucell.com. PLEASE FILL IN AND FAX BACK RESPONSE FORM IN ATTACHED PDF-FILE (FAX (0)20 575 4020
PLEASE RESPOND BEFORE JANUARY 19, 2004
The press release can be downloaded from the following link: http://hugin.info/132631/R/930377/127499.pdf